X0306 4 2016-01-27 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001574591 Dier Mardi C/O PORTOLA PHARMACEUTICALS, INC. 270 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Executive VP and CFO Common Stock 2016-01-27 4 A 0 13750 0.00 A 13750 D Stock Option (Right to Buy) 33.49 2016-01-27 4 A 0 55000 0.00 A 2016-01-27 Common Stock 55000 55000 D Performance Stock Unit 2016-01-27 4 A 0 13750 0.00 A 2020-01-27 Common Stock 13750 13750 D Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2016, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. The option shares shall vest as follows: 1/48th of the shares subject to such option shall vest each month after January 1, 2016, subject to Reporting Person's Continuous Service as of each such date. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follow: 50% of the PSUs will become vested upon achievement of the Issuer's gross product sales target for Andexanet alfa, and up to 50% of the remaining PSUs may vest subject to the timing of approval of Betrixaban by the United States Food and Drug Administration. /s/ Mike Ouimette, as attorney-in-fact 2016-01-27